After a Ph.D. in Immunology, Catherine Larue began her career at Sanofi, Montpellier (France) in the cardiovascular R&D department and participated in the discovery of innovative biomarkers such as troponin I and natriuretic peptides.
She then joined Sanofi Diagnostics Pasteur, at Minneapolis MN (USA) for 3 years where she was responsible for Assay Development in the immunodiagnostic area. She completed an Executive MBA in 2003 and had worked for 7 years as a Director of Business Unit at Bio-Rad. After installing the Biomarkers department in Genfit (Lille, France), she took over the CEO position of the Institute IBBL (Integrated Biobank of Luxembourg). From Jan 2016 to Sept 2017, she was the CEO ad interim of Luxembourg Institute of Health. Since October 1st, she is back to her CEO position at IBBL.
She is an author of 87 publications and filed 13 patents.
Her main expertise relies on cardio-metabolic biomedical research as well as on personalised medicine as she participated in a series of workshops leading to a “white paper” in June 2015.
She served in standardisation committees at AACC and IFCC for 15 years; she also created and chaired the “Biomarkers Group” in the Competitiveness Bio-cluster (Medicen, Paris). She is currently serving as an expert for the European Commission (H2020 and IMI programmes).